Smith & Nephew plc ADR logo

Smith & Nephew plc ADR (SNN)

Market Open
1 Aug, 15:05
NYSE NYSE
$
30. 45
-0.11
-0.36%
$
13.37B Market Cap
39.73 P/E Ratio
0.75% Div Yield
31,368 Volume
0 Eps
$ 30.56
Previous Close
Day Range
30.32 30.59
Year Range
23.69 31.84
Want to track SNN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 4 days
Smith & Nephew sees turnaround plan kicking in as profit grows

Smith & Nephew sees turnaround plan kicking in as profit grows

Smith & Nephew PLC has said 2025 should show its transformation plan kicking in despite ongoing woes in China after improving trading over the last year. Revenue climbed 4.7% to US$5.8 billion in the year to December 31, the medical equipment maker said Tuesday, aiding an 8.2% increase in trading profit to US$1.1 billion.

Proactiveinvestors | 5 months ago
UK's Smith+Nephew beats annual profit expectations

UK's Smith+Nephew beats annual profit expectations

Smith+Nephew beat analysts' expectations for annual sales and profit on Tuesday, as a recovery in its U.S. knee and hip implant business, along with cost cuts, helped the medical products maker offset the impact of weak demand from China.

Reuters | 5 months ago
Smith & Nephew has to impress in results after ringing warning bell

Smith & Nephew has to impress in results after ringing warning bell

Smith & Nephew PLC has left itself with the mounting task of having to give investors something to cheer about after ringing the warning bell last time out. Ahead of full-year figures on Tuesday, 25 February, AJ Bell analysts noted the medical equipment maker flagged it and chief executive Deepak Nath needed to reassure.

Proactiveinvestors | 5 months ago
Smith & Nephew Getting No Credit For Self-Improvement Efforts

Smith & Nephew Getting No Credit For Self-Improvement Efforts

Smith & Nephew's stock has underperformed, driven by ongoing market share losses in hip and knee markets and pricing pressures in China, raising concerns about its ongoing multiyear restructuring program. The upcoming fourth quarter results may not significantly help, given ongoing market share pressure in major joints, ongoing headwinds in China, and a lack of clear growth engines. Smith & Nephew needs to execute its self-improvement plan effectively to close the value gap and regain investor confidence in its turnaround strategy, particularly in the major joint business.

Seekingalpha | 6 months ago
SNN Stock May Gain on CORIOGRAPH Platform's FDA Clearance for THA

SNN Stock May Gain on CORIOGRAPH Platform's FDA Clearance for THA

Smith & Nephew announces FDA clearance for its CORIOGRAPH platform for total hip arthroplasty.

Zacks | 7 months ago
SNN Stock Might Rise Following FDA Nod for AETOS Stemless

SNN Stock Might Rise Following FDA Nod for AETOS Stemless

Smith & Nephew received FDA 510(k) clearance for a stemless anatomic total shoulder, AETOS Stemless. This represents a significant advancement in shoulder arthroplasty.

Zacks | 7 months ago
Big investors call for break-up of Smith & Nephew, FT reports

Big investors call for break-up of Smith & Nephew, FT reports

Three major investors are pushing medical device maker Smith & Nephew to consider a break-up of the business, the Financial Times reported on Thursday, citing shareholders.

Reuters | 8 months ago
Smith & Nephew: Ready To Reap Demographic, Turnaround Dividends

Smith & Nephew: Ready To Reap Demographic, Turnaround Dividends

Smith & Nephew's Q3 results led to a 13% share price drop due to reduced FY24 guidance, mainly from lower demand in China. Despite short-term challenges, long-term fundamentals remain strong, presenting a buying opportunity at current lower prices. The company's 12-point plan aims to boost growth and margins, focusing on orthopedics, productivity, and accelerating growth in advanced wound management and sports medicine.

Seekingalpha | 8 months ago
Smith & Nephew plc (SNN) Q3 2024 Earnings Conference Call Transcript

Smith & Nephew plc (SNN) Q3 2024 Earnings Conference Call Transcript

Smith & Nephew plc (NYSE:SNN ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 AM ET Company Participants Deepak Nath - CEO & Director John Rogers - CFO & Executive Director Conference Call Participants Jack Reynolds-Clark - RBC Capital Management David Adlington - J.P. Morgan Hassan Al-Wakeel - Barclays Robert Davies - Morgan Stanley Richard Felton - Goldman Sachs Graham Doyle - UBS Lisa Clive - Bernstein Julien Dormois - Jefferies Deepak Nath Good morning, and welcome to the Smith & Nephew third quarter trading update.

Seekingalpha | 9 months ago
Smith & Nephew slashes annual revenue forecast on weak China

Smith & Nephew slashes annual revenue forecast on weak China

British medical equipment maker Smith & Nephew cut its annual underlying revenue growth forecast on Thursday to 4.5% from the previous outlook range of 5% to 6%, primarily hurt by challenges in its surgical businesses in China.

Reuters | 9 months ago
SNN Stock May Gain Following the Co-Marketing Deal With JointVue

SNN Stock May Gain Following the Co-Marketing Deal With JointVue

Smith & Nephew and JointVue announce a co-marketing agreement for the latter's OrthoSonic 3D Surgery Planning Technology.

Zacks | 9 months ago
SNN Boosts Knee Revision Surgery With Its LEGION Hinged Knee System

SNN Boosts Knee Revision Surgery With Its LEGION Hinged Knee System

Smith & Nephew introduces the LEGION Hinged Knee System with OXINIUM Technology, elevating knee revision surgery through innovation.

Zacks | 9 months ago
Loading...
Load More